Emergent BioSolutions (EBS) announced a contract modification has been secured to deliver CNJ-016 to the Administration for Strategic Preparedness and Response, part of the U. S. Department of Health and Human Services, for smallpox preparedness. ASPR exercised an option from its existing 10-year contract for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions expands NARCANDirect online distribution network
- Emergent BioSolutions Secures $62.4M ASPR Contract Modification
- Emergent BioSolutions secures $62.4M contract modification for BAT
- Emergent BioSolutions announces addition to Russell 3000 Index
- Emergent BioSolutions teams up with Victoria’s Voice Foundation